Ryan Wolfley, PA
Physician Assistant · Pocatello, IDNPI 1659035301
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,637 and has fallen 92.5% since, to $199 in 2025. Among physician assistant clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$722
- Otsuka America Pharmaceutical, Inc.$510
- Teva Pharmaceuticals USA, Inc.$499
- Alkermes, Inc.$430
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,47599%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,433 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,117 |
| Neurocrine Biosciences, Inc. | 18 | $722 |
| Otsuka America Pharmaceutical, Inc. | 29 | $510 |
| Teva Pharmaceuticals USA, Inc. | 39 | $499 |
| Alkermes, Inc. | 21 | $430 |
| Johnson & Johnson | 14 | $340 |
| Axsome Therapeutics, Inc. | 9 | $260 |
| Ironshore Pharmaceuticals Inc. | 16 | $255 |
| Supernus Pharmaceuticals, Inc. | 15 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $151 |
| Corium, LLC | 9 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $87 |
| Lundbeck LLC | 4 | $74 |
| Eisai Inc. | 2 | $69 |
| Indivior Inc. | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $54 |
| E.r. Squibb & Sons, L.L.C. | 1 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Braeburn Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$363
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
- Auvelity$107
How this compares
$6,532 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 62 | $86,840 |
| Invega SustennaPaliperidone Palmitate | 18 | $45,514 |
| AristadaAripiprazole Lauroxil | 16 | $41,048 |
| Risperdal ConstaRisperidone Microspheres | 11 | $21,910 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,890 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $13,920 |
| DayvigoLemborexant | 24 | $9,896 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,049 |
| Lurasidone Hcl | 17 | $5,428 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $3,578 |
| Clozapine | 40 | $3,379 |
| Aripiprazole | 18 | $2,430 |
| Olanzapine | 41 | $1,187 |
| Duloxetine Hcl | 17 | $899 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,433 | $86,84062 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $340 | $67,42429 claims |
| Alkermes, Inc.Aristada, Lybalvi | $430 | $60,93729 claims |
| Axsome Therapeutics, Inc.Auvelity | $260 | $13,92017 claims |
| Eisai Inc.Dayvigo | $69 | $9,89624 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $151 | $6,04912 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $30232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.
Other physician assistant in Pocatello
- Charlynn PerkesPocatello$5K
- Benjamin KernsBoise$100K
- Brian BizikTwin Falls$81K
- Autumn HeumanBoise$28K
- James WalkerNampa$21K
- Melissa McClenahanMeridian$19K
- Kimberly PortchCoeur D Alene$17K
- Arthur NeaseMeridian$16K
- Chase BealBurley$16K
- Alexander ArhetsMeridian$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.